Egalet Corporation (EGLT) has risen sharply, recording gains of 33.44% in the past 4 weeks. However, the stock has corrected -0.49% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 32.08% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 12.18% and the 50-Day Moving Average is 33.63%. Egalet Corporation (NASDAQ:EGLT): On Fridays trading session , Opening price of the stock was $8.45 with an intraday high of $8.57. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $8.08. However, the stock managed to close at $8.1, a loss of 3.57% for the day. On the previous day, the stock had closed at $8.4. The total traded volume of the day was 560,197 shares.
The company Insiders own 26.2% of Egalet Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -8.03% . Institutional Investors own 67.74% of Egalet Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -12.47%.
Egalet Corporation is a specialty pharmaceutical company developing, manufacturing and commercializing medicines for patients with acute and chronic pain. The Companys products include OXAYDO and SPRIX Nasal Spray. OXAYDO is the immediate-release oxycodone product formulated to deter abuse via snorting, for the management of acute and chronic moderate to severe pain where an opioid is appropriate. SPRIX Nasal Spray is the nasal spray formulation of non-steroidal anti-inflammatory drug (NSAID), ketorolac, used for short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company is developing two late-stage product candidates using Guardian Technology. The lead program, Egalet-001 is an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002 is an abuse-deterrent, extended-release, oral oxycodone formulation.